|
FR2698880B1
(fr)
|
1992-11-25 |
1995-02-24 |
Inst Nat Sante Rech Med |
Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
|
|
US6737398B1
(en)
|
1999-09-30 |
2004-05-18 |
National Jewish Medical And Research Center |
Modulation of γδ T cells to regulate airway hyperresponsiveness
|
|
WO2001022816A1
(en)
|
1999-09-30 |
2001-04-05 |
National Jewish Medical And Research Center |
MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
|
|
US8178098B2
(en)
|
2001-04-03 |
2012-05-15 |
National Jewish Health |
Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
|
|
US20100081792A1
(en)
|
2001-06-28 |
2010-04-01 |
Smithkline Beecham Corporation |
Ligand
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
US20040161776A1
(en)
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
KR101033196B1
(ko)
|
2002-02-14 |
2011-05-09 |
이뮤노메딕스, 인코오포레이티드 |
항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
|
|
EP1532175B1
(en)
|
2002-03-22 |
2012-10-17 |
Aprogen, Inc. |
Humanized antibody and process for preparing the same
|
|
EP1587838B1
(en)
|
2003-01-10 |
2015-04-15 |
Ablynx N.V. |
Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
|
|
EP1587837B1
(en)
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
WO2005046711A2
(en)
|
2003-11-07 |
2005-05-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
EP1778836B1
(en)
|
2004-08-19 |
2010-08-04 |
University College Cardiff Consultants Limited |
Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
|
|
BRPI0607796A2
(pt)
|
2005-02-18 |
2009-06-13 |
Medarex Inc |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
|
|
NZ556661A
(en)
|
2005-02-18 |
2010-10-29 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
US8338173B2
(en)
|
2005-08-11 |
2012-12-25 |
University College Cardiff Consultants Limited |
Preparation of antigen-presenting human γδ T cells and use in immunotherapy
|
|
BRPI0617546A2
(pt)
|
2005-09-26 |
2011-07-26 |
Medarex Inc |
conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
EP1878440A1
(en)
|
2006-07-13 |
2008-01-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
|
|
WO2009046294A2
(en)
|
2007-10-03 |
2009-04-09 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
ITTO20080313A1
(it)
|
2008-04-22 |
2009-10-23 |
Marco Colombatti |
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
WO2010111625A1
(en)
|
2009-03-27 |
2010-09-30 |
Zymogenetics, Inc. |
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
US8629247B2
(en)
|
2009-04-14 |
2014-01-14 |
Proscan Rx Pharma Inc. |
Antibodies against prostate specific membrane antigen
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
PL2606064T3
(pl)
|
2010-08-16 |
2015-07-31 |
Novimmune Sa |
Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
|
|
UA118950C2
(uk)
|
2011-04-22 |
2019-04-10 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
|
|
AU2013201422B2
(en)
|
2012-01-23 |
2015-04-09 |
Ablynx Nv |
Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
|
|
MX361875B
(es)
|
2012-03-14 |
2018-12-18 |
Regeneron Pharma |
Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
|
|
EP2831109B1
(en)
|
2012-03-28 |
2017-12-06 |
Gadeta B.V. |
Combinatorial gamma 9 delta 2 t cell receptor chain exchange
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
US9745381B2
(en)
|
2012-05-18 |
2017-08-29 |
Scott & White Healthcare (Swh) |
Bispecific scFv immunofusion (BIf)
|
|
WO2013174403A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2013174404A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CA2887047A1
(en)
|
2012-10-05 |
2014-04-10 |
Cornell University |
Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
|
|
DK2924052T3
(da)
|
2012-11-21 |
2019-09-30 |
Pharmabcine Inc |
Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
|
|
WO2014127785A1
(en)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
CN105814082A
(zh)
|
2013-09-26 |
2016-07-27 |
埃博灵克斯股份有限公司 |
双特异性纳米抗体
|
|
DK3105252T3
(da)
|
2014-02-12 |
2019-10-14 |
Michael Uhlin |
Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
|
|
EP3129404B1
(en)
|
2014-04-10 |
2026-01-28 |
LAVA Therapeutics N.V. |
Immunoglobulins binding human vgamma9vdelta2 t cell receptors
|
|
WO2016081518A2
(en)
|
2014-11-17 |
2016-05-26 |
Adicet Bio, Inc. |
Engineered gamma delta t-cells
|
|
CA2979219A1
(en)
|
2015-03-10 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind psma
|
|
US11000603B2
(en)
|
2015-04-14 |
2021-05-11 |
Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. |
Multi-specific binding conjugate, related pharmaceutical compositions and use
|
|
CN104829730A
(zh)
|
2015-04-14 |
2015-08-12 |
苏静 |
一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
|
|
US10844122B2
(en)
|
2015-05-06 |
2020-11-24 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
|
|
PT3294768T
(pt)
|
2015-05-13 |
2019-11-05 |
Ablynx Nv |
Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
LT3353212T
(lt)
|
2015-09-23 |
2021-12-27 |
Regeneron Pharmaceuticals, Inc. |
Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
|
|
WO2017122019A1
(en)
|
2016-01-12 |
2017-07-20 |
Crescendo Biologics Limited |
Immunoconjugates that bind prostate specific membrane antigen (psma)
|
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
KR102466763B1
(ko)
|
2016-04-13 |
2022-11-11 |
오리맵스 리미티드 |
항- psma 항체 및 이의 용도
|
|
CN109195992A
(zh)
|
2016-04-29 |
2019-01-11 |
本康生物制药（深圳）有限公司 |
多特异性结合偶联物、相关的药物组合物及应用
|
|
CA3032304A1
(en)
|
2016-07-29 |
2018-02-01 |
New York University |
Gamma delta t cells as a target for treatment of solid tumors
|
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
CN110198955A
(zh)
|
2016-11-23 |
2019-09-03 |
哈普恩治疗公司 |
前列腺特异性膜抗原结合蛋白质
|
|
WO2018140831A2
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
MX2019013142A
(es)
*
|
2017-05-05 |
2019-12-16 |
Amgen Inc |
Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
WO2019055841A1
(en)
*
|
2017-09-14 |
2019-03-21 |
Denali Therapeutics Inc. |
ANTI-TREM2 ANTIBODIES AND METHODS OF USE
|
|
TWI687227B
(zh)
|
2017-10-03 |
2020-03-11 |
生倍科技股份有限公司 |
用於t細胞免疫療法之組合及其用途
|
|
RU2020135920A
(ru)
|
2018-04-05 |
2022-05-05 |
Новартис Аг |
Триспецифические связывающие молекулы против форм рака и пути их применения
|
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
|
SG11202012342WA
(en)
|
2018-06-18 |
2021-01-28 |
Eureka Therapeutics Inc |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
WO2019246514A1
(en)
*
|
2018-06-21 |
2019-12-26 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-psma x anti-cd28 antibodies and uses thereof
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020060406A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Lava Therapeutics B.V. |
Novel bispecific antibodies for use in the treatment of hematological malignancies
|
|
WO2020077257A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113993893A
(zh)
|
2019-02-01 |
2022-01-28 |
拉法医疗有限公司 |
新cd40结合抗体
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP3965818A4
(en)
|
2019-05-08 |
2023-05-31 |
Janssen Biotech, Inc. |
MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY
|
|
CA3145523A1
(en)
|
2019-08-16 |
2021-02-25 |
GammaDelta Therapeutics Limited |
Therapeutic uses of anti-tcr delta variable 1 antibodies
|
|
US20220290101A1
(en)
|
2019-08-16 |
2022-09-15 |
GammaDelta Therapeutics Limited |
Ex vivo gamma delta t cell populations
|
|
EP3792283A1
(en)
|
2019-09-16 |
2021-03-17 |
Lava Therapeutics B.V. |
Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
|
|
KR20220147631A
(ko)
|
2020-02-27 |
2022-11-03 |
얀센 바이오테크 인코포레이티드 |
면역 반응을 조절하기 위한 물질 및 방법
|
|
IL296358A
(en)
|
2020-03-13 |
2022-11-01 |
Janssen Biotech Inc |
Materials and methods for modulating delta chain mediated immunity
|
|
WO2021231434A1
(en)
|
2020-05-12 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
|
CN116323667A
(zh)
|
2020-07-08 |
2023-06-23 |
拉法医疗股份有限公司 |
结合PSMA和γ-δT细胞受体的抗体
|
|
AR123935A1
(es)
|
2020-10-28 |
2023-01-25 |
Janssen Biotech Inc |
COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
|
|
IL303045A
(en)
|
2020-12-10 |
2023-07-01 |
Lava Therapeutics N V |
Antibodies that bind gamma-delta t cell receptors
|
|
CA3208069A1
(en)
|
2021-03-09 |
2022-09-15 |
Mary Ellen Molloy |
Combination therapy with immune cell engaging proteins and immunomodulators
|